Phase 2 Ovarian Cancer Trial, Not Yet Recruiting NCT07432594 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Not Yet Recruiting

NCT07432594
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are 18 years of age or older.
  • People who have been diagnosed through a tissue biopsy with high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
  • People whose cancer has been classified as an advanced stage (stage 3C or stage 4) using an international staging system for gynaecological cancers.
  • People whose general health and ability to carry out daily activities falls within a certain range on a standard medical scale (confirm with trial site).
  • People whose cancer has been assessed by a specialist team using scans (and possibly keyhole surgery) as unlikely to be fully removed by surgery at this stage.
  • People who have at least one tumour that can be measured using standard imaging criteria.
  • People whose major organ function (such as heart, liver, and kidneys) is broadly within a normal range.
  • People who are willing to provide tumour tissue, blood, and fluid samples from the abdomen for research purposes.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose cancer is a type other than high-grade serous carcinoma.
  • People who have previously received any type of cancer treatment.
  • People who have a history of autoimmune disease or who need medication that suppresses the immune system.
  • People who have a known allergy to any of the components in the study drug.
  • People who are pregnant or currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026

Contact this trial

Principal Investigator: Ning Li, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phone: 8610-87787211

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
1 March 2026
Est. completion
30 May 2027

Primary endpoints

Rate of R0 resection

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov